Oncology

Multiple Myeloma

Expert Roundtables Podcast: Defining the Needs of Today’s Patients With Relapsed/Refractory Multiple Myeloma

expert roundtables by David E. Avigan, MD; Irene M. Ghobrial, MD; Saad Z. Usmani, MBBS, MD, MBA, FACP, FRCP, FASCO

Overview

As more new treatments for relapsed/refractory multiple myeloma continue to become available, understanding patient needs and preferences regarding treatment will continue to be critical. Challenges remain in balancing innovative treatment with the risks of toxicity and resistance while working to optimize patient quality of life and developing a cure for the disease.

References

Bylund CL, Eggly S, LeBlanc TW, et al. Survey of patients and physicians on shared decision-making in treatment selection in relapsed/refractory multiple myeloma. Transl Behav Med. 2023;13(4):255-267. doi:10.1093/tbm/ibac099

LeBlanc MR, Hirschey R, Leak Bryant A, LeBlanc TW, Smith SK. How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review. Qual Life Res. 2020;29(6):1419-1431. doi:10.1007/s11136-019-02392-6

Neupane K, Khader AHSA, Dahal R, et al. Unmet needs in multiple myeloma and potential solutions: a systemic literature review. Blood. 2024;144(suppl 1):6907. doi:10.1182/blood-2024-198626

Ni B, Hou J. Promising therapeutic approaches for relapsed/refractory multiple myeloma. Hematology. 2022;27(1):343-352. doi:10.1080/16078454.2022.2045724

Profile

David E. Avigan, MD

Chief, Division of Hematology and Hematologic Malignancies

Director, Cancer Center

Beth Israel Deaconess Medical Center

Senior Vice President, Cancer Services

Beth Israel Lahey Health

Professor of Medicine

Harvard Medical School

Boston, MA

Profile

Irene M. Ghobrial, MD

Professor of Medicine and Lavine Family Chair for Preventative Cancer Therapies
Senior Vice President for Experimental Medicine
Director, Center for Early Detection and Interception of Blood Cancers
Co-Leader, Dana-Farber/Harvard Cancer Center Lymphoma and Myeloma Program
Dana-Farber Cancer Institute
Boston, MA